Adaptive decision-making of breast cancer mammography screening: A heuristic-based regression model

Operational research techniques applied throughout cancer care services: a review

“…The majority of breast cancer screening papers either compare mammogram screening strategies (Brailsford, Harper, & Sykes, 2012;Madadi, Zhang, & Henderson, 2015;Tejada et al, 2014) or optimise the decision of whether to mammogram or not each year (Ayer, Alagoz, & Stout, 2012;O'Mahony et al, 2015;Ayer, Alagoz, Stout, & Burnside, 2016;Wang & Zhang, 2017). Of these, Madadi et al (2015) consider an especially large set of screening strategies.…”

“…Of these, Madadi et al (2015) consider an especially large set of screening strategies. There has been a shift in focus away from the fixed-interval policies that are common in practice, to consideration of dynamic screening intervals Brailsford et al, 2012;Tejada et al, 2014;Madadi et al, 2015;O'Mahony et al, 2015;Ayer et al, 2016;Wang & Zhang, 2017). These dynamic intervals may vary based on changing risk, age and adherence to screening guidelines.…”

“…If more accurate screening tests are introduced in future, the ongoing appropriateness of the screening interval can be judged by this model. Both simulation (Arrospide et al, 2015;Brailsford et al, 2012;Tejada et al, 2014Tejada et al, , 2015 and analytical Ayer, 2015;Ayer et al, 2016;Madadi et al, 2015;O'Mahony et al, 2015;Wang & Zhang, 2017) techniques are used to model breast cancer progression and the screening process, as in earlier papers. There are some very sophisticated models combining multiple approaches, for example Tejada et al (2014; combine system dynamics with detailed discrete event simulations.…”

“…Contrastingly, O'Mahony et al (2015) purposely built a relatively simple mathematical model, validated its results against a more complex simulation and found that their model was detailed enough to demonstrate that different risk levels have different optimal screening intervals. The performance measures assessed by the models are diverse and include mortality measures (Arrospide et al, 2015;Brailsford et al, 2012;Madadi et al, 2015;Tejada et al, 2014;Wang & Zhang, 2017), quality-adjusted life year measures Ayer, 2015;Ayer et al, 2016;Madadi et al, 2015;Tejada et al, 2014) …”

“…Holder and LLagostera (2008) model how best to apply photodynamic therapy to deep tissue cancers, and assess whether the only drug approved in the USA for this treatment at the time would yield acceptable results. Tejada et al (2014), Arrospide et al (2015), Madadi et al (2015), Wang and Zhang (2017) and Deviations from prescribed radiation doses in tumour, surrounding organs and normal tissue Lee and Zaider (2008) and Ferrari et al (2014) Number of needles, number of radioactive seeds They develop biological models of the concentration of the drug in different tissues, and the rate at which cellular damage occurs when the drug is activated with light. Their linear model to optimise the application of the light source is adapted from a model for external radiotherapy planning.…”